Goldman Sachs: The short-term reduction in production by Contemporary Amperex Technology may cause lithium prices to bottom out, but the overall prospects for the lithium cycle are still very negative.
Goldman Sachs analysts Trina Chen and Joy Zhang said in a client report on Thursday that Ningde Times' production cuts may provide a 'short-term' bottom for lithium prices in the years-long bear market, temporarily alleviating concerns of oversupply. However, they emphasized that the overall outlook for the lithium cycle remains very 'negative'.
Lithium carbonate "long-lost surge"! Contemporary Amperex Technology plans to adjust the production arrangement of lithium carbonate in Yichun. Industry analysis believes that "production suspension is mainly due to cost."
1. Regarding the rumored suspension of lithium production in Jiangxi, Contemporary Amperex Technology expressed to the Cailian Press journalists that based on the recent situation in the lithium carbonate market, the company plans to adjust the production arrangement of Yichun lithium carbonate. 2. An informed source informed the Cailian Press journalists that Contemporary Amperex Technology has not yet taken any measures to stop, and further communication and coordination are needed before a decision is made. 3. Industry insiders analyze that the main reason for the suspension at this time is cost-related.
With a scale exceeding 5 billion yuan, contemporary amperex technology's new fund has landed in Xiamen.
Recently, Contemporary Amperex Technology has launched a new fund in Xiamen with a scale of over 5 billion yuan. LPs include local state-owned asset funds in Xiamen, as well as Zhejiang Tongxiang City, Ningde City in Fujian Province, and Luoyang City's state-owned asset funds. Contemporary Amperex Technology is also constructing the phase one of an electrochemical energy storage system project in Xiamen, aiming to create a top-notch platform for energy storage system research and development testing, as well as technological innovation verification.
The price of lithium carbonate futures has surged, with a single-day increase of nearly 0.03 million contracts. The rumor of production suspension at Contemporary Amperex Technology has been confirmed. Will there be a bottoming out and rebound?
① Market experts have stated that if there is a significant reduction in the output of lithium carbonate in the coming months, the destocking level in September and October may exceed expectations; ② As the consumer market enters the peak season of "Golden September and Silver October", the fundamentals have improved recently and a turning point in inventory has already emerged.
Tsubota Lab has signed an exclusive implementation license agreement with shenyang xingqi pharmaceutical.
On the 5th, Tobita Lab <4890> announced that they have signed a patent license agreement with China's ophthalmology drug manufacturer Shenyang Xingqi Pharmaceutical (hereinafter referred to as Xingqi) to grant exclusive rights to certain patents in specific regions.
UBS Group: Contemporary Amperex Technology suspends lithium production in Jiangxi, China's lithium prices hit bottom.
UBS estimates that the suspension of Contemporary Amperex Technology's lithium business in Jiangxi will lead to an 8% decrease in China's monthly production of lithium carbonate. The lithium price is expected to rise by 11%-23% within the year and will be supported at $8600/ton.
Another unreasonable suppression! The U.S. House of Representatives has passed the Biosecurity Act, and wuxi apptec and wuxi bio have quickly responded.
①The U.S. House of Representatives passed the draft of the Biosecurity Act (H.R.8333) with 306 votes in favor and 81 votes against. ②Wuxi Apptec, Wuxi Bio, and other companies strongly opposed it. ③This bill still needs to be voted on by the Senate and the versions passed by both houses need to be reconciled before it can be submitted to the U.S. President for signing into law.
August is the peak period of profitability for pig enterprises, with daily profits exceeding one billion yuan. | Industry News
①In August, the pig market continued to recover, with sales prices of major pig companies reaching a new high this year; ②The peak of profitability for pig companies still focuses on reducing costs and increasing efficiency. Muyuan Foods, Shennong Group, and Wens Foodstuff Group have all reduced their fully loaded costs to below 14 yuan/kg; ③Some industry insiders believe that breeding companies will continue to maintain a considerable profit trend this year.
chongqing zhifei biological products' 23-valent pneumonia vaccine joins the "price reduction group" just one year after its launch.
① Chongqing Zhifei Biological Products 23-valent pneumococcal polysaccharide vaccine has lowered its online price by nearly 30% in provinces such as Jiangsu and Jilin; ② Currently, China's pneumococcal vaccine market is showing a competitive situation of "wrestling" between overseas MNCs and domestic companies, and more and more companies are expanding their presence in this field; ③ Industry experts believe that in order to occupy the market, companies can only choose to actively reduce prices.
Internet security vendors are experiencing widespread losses, and the industry's downward trend is difficult to conceal due to seasonal factors. It is urgent to find new sources of revenue.
①In the first half of the year, only 3 out of the top 20 companies in the csi information security industry achieved profitability, and all of the top 10 suffered losses. ②According to interviews conducted by Cailian Press reporters, the losses were mainly caused by the periodic nature of projects and seasonal factors affecting receivables. ③Analysts believe that in the context of downstream customers, especially those in the government sector, facing significant financial pressures and declining purchasing power, the network security industry needs to expand its market-oriented customer base.
Did Softcom Power's loss of 0.154 billion in the first half of the year enable the company's performance in the long term? | Interpretations
In the first half of 2024, Pactera achieved revenue of 12.526 billion yuan, a year-on-year increase of 45.98%; net loss attributable to the parent company was 0.154 billion yuan, a year-on-year decrease of 176.17%; Under the wave of AI at the edge, the revenue generated in the high-tech and manufacturing field reached 4.094 billion yuan, a year-on-year increase of 268.73%.
The batch issuance of the quadrivalent HPV vaccine has dramatically decreased, and chongqing zhifei biological products' revenue and net profit have both declined. Interpretation of the financial report.
Due to the decrease in sales volume of H1's main products, Chongqing Zhifei Biological Products reported a decrease in revenue and net income in its semi-annual report. The volume of Merck's quadrivalent HPV vaccine, which the company represents, decreased by more than 90% compared to the previous year. With the accelerated development of domestically-produced nine-valent HPV vaccines, the company's pressure will further increase.
Suzhou Maxwell Technologies' revenue increased by nearly 70% in the first half of the year, but there is now a "hidden concern" as the inventory book value exceeds 10 billion yuan. | Interpretation of financial statements
① The leading company in heterojunction devices saw both revenue and net income increase in the first half of the year, but the inventory's book value reached 10.983 billion yuan, accounting for 45.14% of the total assets for the period; ② With a high inventory scale, it is a common situation among many photovoltaic equipment manufacturers, and the risk of inventory backlog or price decline may have adverse effects on the company's operations and performance.
Intense market competition combined with inventory reduction, Shenzhen Kangtai Biological Products' performance in the first half of the year has significantly declined | Interpretation of financial reports
①Affected by market competition and factors such as inventory reduction, the total revenue and net income attributable to the mother of shenzhen kangtai biological products declined in H1. ②The sales revenue of the business sector with the largest revenue contribution of the company decreased by more than 30% year-on-year. ③The accounts receivable of shenzhen kangtai biological products continued to climb, with a substantial decrease in cash flow.
Gross margin decreases, research and development investment increases, Thunder Software Technology's net profit in the first half of the year has declined by over 70% year-on-year, interpretations.
In H1 2024, Thunder Software Technology achieved a revenue of 2.401 billion yuan, a decrease of 3.39% year-on-year; net income attributable to the parent company was 0.104 billion yuan, a decrease of 73.1% year-on-year. The slowdown in the smart automobile business is due to the long acceptance cycle of the complete vehicle plant and the untimely delivery of some vehicle models. The company stated that it will continue to explore the global market and continue to invest in innovative applications.
ODM and OEM business driving the company's sales scale growth. Lens Technology's net income in the first half of the year increased by 55% YoY. | Interpretations
① The consumer electronics industry has shown a clear trend of recovering terminal demand, with lens technology's net income in the first half of the year increasing by more than fifty percent year-on-year. ② With the continuous innovation of AI smartphones by major mobile phone brands, it may drive the arrival of a new round of replacement cycles, and companies related to the industry chain are expected to benefit.
Industry demand decline drags down hithink royalflush information network's net income by 21% year-on-year in the first half of the year | Financial Report View
The company's revenue in the first half of the year was 1.389 billion yuan, a decrease of 5.51% compared to the same period last year. R&D expenses increased by 5.12% year-on-year.
Energy storage shipments "overtaking" power, eve energy co.,ltd. H1 performance decline, energy storage batteries gradually becoming the focus of the business | Financial report interpretation
Eve Energy Co., Ltd. achieved a revenue of 21.659 billion yuan in H1, a year-on-year decrease of 5.73%; its net income attributable to shareholders was 2.137 billion yuan, a year-on-year decrease of 0.64%. In Q2, the company's shipment of energy storage batteries exceeded that of power batteries, resulting in a year-on-year increase of 9.93% in revenue from energy storage batteries in the first half of the year, while revenue from power batteries decreased year-on-year.
The chiNext price index continues to fall! It is less than 5% away from the new low of the year. Only 10% of the stocks have seen gains this year. These sectors are relatively resilient against pressure.
①Today, the chinext price index continued to hit a new low in the stage, with only a 4.3% difference from the lowest point of the year in the mid-term on February 5. ②In addition to the chinext price index, the north 50 index also fell below the previous low point of the year, and the sci-tech innovation 100 index, the csi 500 index, and the shenzhen component index are not far from the low point. ③Currently, the proportion of stocks that have increased in the stock market this year has fallen to 10.3%, with the "red stocks" in the banking sector taking the lead.
The gross margin of injection products in the solution category has declined, and the imeik technology development's Q2 performance growth rate has dropped to single digits| Speed reading announcement.
①Imeik Technology Development's H1 revenue and net income growth rate slowed down. ②The gross margin of solution injection products has declined, and its proportion in total revenue has further decreased. ③In addition to laying out research and development pipelines for botulinum toxin, GLP-1 drugs, the company is also further expanding in the medical beauty equipment field.